Replies to post #212561 on Biotech Values

[maverick_1]

https://video.foxnews.com/v/5513640393001/?#sp=show-clips

As one can see Dr. Andrew Sloan is involved with DCVAX L for ndGBM for many, many years with results in the near term.
Ohio trial locations:

[ed States, Ohio
University of Cincinnati Cancer Institute
Cincinnati, Ohio, United States, 45267
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States, 44106
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio State University
Columbus, Ohio, United States, 43210
OhioHealth
Columbus, Ohio, United States, 43214

https://clinicaltrials.gov/ct2/show/study/NCT00045968?show_locs=Y#locn

Not surprisingly, my own findings and others demonstrate that medical institutions and neurosurgeons are BIASED whether Dr. Keith Black of Cedar Sinai doing Maria Menounos; https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132694011

UCSF: Sean Parker's CEO for his The Parker Institute for Cancer Immunotherapy hails from UCSF! which is probably why this LONG key trial has been extended many times: July 28 -- Yonemura v. Powers, "Final Resolution." https://www.pacermonitor.com/public/case/9970453/Yonemura_v_Powers_et_alI

Dr. Reardon of Boston's Farber Center has been the sponsor of failed CLDX's GBM trials. ETC ETC

I have commented on NVCR's Optune in late 2014: a year BEFORE NVCR's IPO:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=117522379

I introduced Marzan to the company in question who got his fellow compatriots on board.

And don't forget the same analyst that wrote up what you and I own did this: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132735574

Did the above since you'd like me and require substance.

Regards.

DIFFERENT STROKES FOR DIFFERENT FOLKS